רווח לפני תשלום ריבית, מסים ופחת: sanofi.com (SNY)

The French behemoth Sanofi (SNY) relies on high-demand vaccines and treatments for chronic pathologies, while the success of Dupixent guarantees a highly reliable cash flow. EBITDA_Co monitoring confirms this resilience, where 22337.53 represents the current metric value. An impeccable image as a classic manufacturer and a positive business restructuring maintain a high level of trust from the global medical community.

This metric measures the actual cash flow from core operations before deducting depreciation and interest. It reflects the business's ability to generate liquidity to cover operating expenses amid inflation. Analyzing actual EBITDA allows for the identification of hidden margin compression resulting from rising costs. For Sanofi (SNY), this metric confirms the defensive qualities of the business. Stable revenue from immunology drugs ensures capital resilience during the company's restructuring.